West Warwick, RI (PRWEB) January 21, 2013
Blood Centers of America, Inc. (BCA) announced today it will play a leadership role in representing North American independent blood centers at this year's Phacilitate Cell & Gene Therapy Forum to be held January 28-30, 2013 in Washington, D.C.
BCA will be hosting one-on-one meetings with senior executives of leading cell therapy and cell-based immunotherapy companies, participating in sessions and high-profile networking events, and showcasing BCA member capabilities in the event's 3-day tradeshow.
"Participating in what is often described as one of the leading cell therapy industry conferences of the year is a great way to launch our 2013 initiative to raise the profile of BCA in the cell therapy industry and engage in one-on-one discussions about what BCA has to offer companies in the cell therapy sector," stated BCA's newly appointed CEO, Bill Block.
"BCA is a network of centers geographically dispersed throughout North America with considerable experience in collecting, processing and distributing regulatory-compliant, clinical-grade biologial materials", continued Block. "We are keen to engage cell therapy leadership in a discussion about how we can leverage BCA member infastructure and capabilities in the development and processing of cell therapy products and their safe and cost-effective delivery to patients."
BCA is a member-owned organization comprised of 37 independent blood centers geographically dispersed throughout the North America, providing more than 46% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, BCA members provide a myriad of other services in cell therapies, blood management, therapeutic apheresis, tissue and cord blood banking, etc.
BCA provides thousands of units of biological materials annually to life science researchers, clinicians, therapeutic companies, or companies doing medical device, diagnostic or therapeutic development work.
BCA assists cell therapy companies with securing reliable and compliant sources for the cells used in their therapeutic products and/or pre-clinical research. Where a client need exceeds the capacity of a single center, BCA can assist with putting in place a multi-center supply agreement around cell collections, processing, storage or other handling.
In 2012, BCA generated over $6 million in custom products and services to cell therapy companies including patient-donor collections for autologous cell therapies in clinical trial and commercial distribution.
For more information about how BCA and its services, see http://www.bca.coop.
About the Cell & Gene Therapy Forum
Phacilitate's 9th Annual Cell & Gene Therapy Forum is firmly established as the world’s leading strategy and partnering event for senior decision makers from the global cell therapy, gene therapy and tissue engineered product sectors.
The Cell & Gene Therapy Forum is held along side the Vaccine Forum and the Protein Therapeutics Forum. For more information, see http://www.cgt-forum.com.